Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) PT at $79.70

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eleven have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $83.50.

MIRM has been the topic of a number of recent research reports. Stifel Nicolaus set a $89.00 price objective on Mirum Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 11th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday, October 8th. Morgan Stanley upped their target price on shares of Mirum Pharmaceuticals from $75.00 to $81.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Finally, JPMorgan Chase & Co. raised their target price on shares of Mirum Pharmaceuticals from $53.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, September 12th.

Mirum Pharmaceuticals Trading Up 0.6%

MIRM opened at $68.11 on Wednesday. Mirum Pharmaceuticals has a 1-year low of $36.88 and a 1-year high of $78.54. The stock has a market capitalization of $3.50 billion, a PE ratio of -79.20 and a beta of 0.75. The company has a current ratio of 3.31, a quick ratio of 2.97 and a debt-to-equity ratio of 1.06. The firm has a 50-day moving average price of $72.95 and a two-hundred day moving average price of $58.94.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million for the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. Mirum Pharmaceuticals’s revenue was up 47.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.30) earnings per share. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, August 11th. The shares were sold at an average price of $62.00, for a total transaction of $2,480,000.00. Following the completion of the sale, the chief executive officer owned 138,641 shares of the company’s stock, valued at approximately $8,595,742. The trade was a 22.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Laura Brege sold 17,000 shares of the company’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $74.40, for a total transaction of $1,264,800.00. Following the sale, the director owned 15,703 shares of the company’s stock, valued at $1,168,303.20. The trade was a 51.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 66,578 shares of company stock valued at $4,472,824. 14.36% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MIRM. CWM LLC grew its position in shares of Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company’s stock worth $27,000 after buying an additional 428 shares during the period. MCF Advisors LLC boosted its stake in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the last quarter. Comerica Bank grew its holdings in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. Quarry LP bought a new stake in Mirum Pharmaceuticals in the first quarter valued at approximately $56,000. Finally, Osaic Holdings Inc. raised its holdings in Mirum Pharmaceuticals by 46.5% in the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.